Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) will be hosting a conference call at 4:30 PM eastern time on 4th August 2020, to discuss its 2Q20 financial results with the investment community.
A live webcast with presentations will be available on the Internet by visiting the Company website www.rigel.com
Earnings Expectation
Rigel Pharmaceuticals, Inc. is reporting second quarter financial results on Tuesday 4th August 2020, after market close.
According to analysts surveyed by Thomson Reuters, RIGL is expected to report 2Q20 loss of $ 0.13 per share from revenue of $ 13.75 million.
For the full year, analysts anticipate top line of $ 102.83 million, while looking forward to loss of $ 0.27 per share bottom line.
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of small molecule drugs for the treatment of immune and hematologic disorders, cancer, and rare diseases. The companys clinical programs include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; and Phase III clinical study for autoimmune hemolytic anemia. Its clinical programs also comprise R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) program, which is in Phase I clinical study for autoimmune and inflammatory diseases.
